Immunovaccine ( Immunovaccine)

Primary tabs

Immunovaccine's picture

Management

Contact Address

About Immunovaccine

Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system.

Immunovaccine press release, blog etc

Wed, 12/07/2022 - 19:12 IMV Shareholders Approve Reverse Stock Split at 88%
Fri, 09/30/2022 - 06:07 IMV Provides an Update on The VITALIZE Trial
Thu, 04/28/2022 - 08:37 IMVs Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting
Thu, 04/07/2022 - 21:53 IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting
Wed, 04/06/2022 - 00:27 IMV to Present at IMMUNOLOGY 2022, the AAI Annual Meeting
Thu, 02/17/2022 - 08:15 IMV to Host a Webcast to Highlight its Immune-Educating DPX Platform
Wed, 01/12/2022 - 11:56 IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA (pembrolizumab) in Patients with r/r DLBCL
Wed, 12/22/2021 - 06:10 IMV Appoints Andrew Hall as Chief Executive Officer
Tue, 12/21/2021 - 05:18 IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts
Mon, 12/20/2021 - 05:56 IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility
Wed, 12/01/2021 - 23:37 Role of B Cells Induced by IMVs Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress
Tue, 11/30/2021 - 20:06 IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer
Mon, 11/22/2021 - 21:18 IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference
Mon, 11/22/2021 - 19:02 IMV Inc. Announces Chief Financial Officer to Retire
Tue, 11/09/2021 - 19:40 Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
Thu, 10/07/2021 - 15:31 Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
Fri, 10/01/2021 - 05:38 Potential Response Predictors to IMVs Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
Wed, 09/29/2021 - 21:05 IMVs DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
more

InfoBox

HomePagewww.imvaccine.com
Facebookwww.facebook.com/pages/Immunovaccine-Inc/224346854247738
Twittertwitter.com/#!/immunovaccine
LinkedInwww.linkedin.com/company/immunovaccine-inc-